Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting.

IF 9.4 1区医学 Q1 HEMATOLOGY

Experimental Hematology & Oncology Pub Date : 2024-02-16 DOI:10.1186/s40164-024-00486-7

Xubo Gong, Xin He, Lin Wang, Teng Yu, Weiwei Liu, Huiying Xu, Lan Jin, Xiang Li, Bin Zhang, Zhihua Tao, Wenbin Qian

引用次数: 0

Abstract

Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis. The combination of venetoclax (VEN) with hypomethylating agents has been established as the standard treatment for elderly or medically unfit AML patients unable to undergo intensive chemotherapy. Despite this, the availability of novel VEN-based therapies specifically tailored for those with R/R AML remains scarce. Here, we provide a comprehensive overview of the latest data presented at the 65th American Society of Hematology Annual Meeting, shedding light on the progress and efficacy of VEN-based therapies for R/R AML.

查看原文本刊更多论文

基于 Venetoclax 治疗复发或难治性急性髓性白血病：2023 年 ASH 年会的最新进展。

复发性或难治性（R/R）急性髓性白血病（AML）患者通常对传统化疗的反应有限，导致预后不良。venetoclax（VEN）与低甲基化药物联用已被确立为治疗无法接受强化化疗的老年或体质不佳急性髓性白血病患者的标准疗法。尽管如此，专为R/R急性髓细胞白血病患者量身定制的基于VEN的新型疗法仍然很少。在此，我们将全面概述第 65 届美国血液学会年会上公布的最新数据，揭示基于 VEN 的治疗 R/R AML 的进展和疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental Hematology & Oncology Medicine-Oncology

CiteScore

12.60

自引率

7.30%

发文量

审稿时长

6 weeks

期刊介绍： Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.